Mati Therapeutics Expands Patent Portfolio

AUSTIN, Texas, June 30, 2014 (GLOBE NEWSWIRE) -- Mati Therapeutics Inc. ("Mati") announced today that it has been granted U.S. Patent No. 8,747,884 entitled "Nasolacrimal Drainage System Implants For Drug Therapy." The patent provides coverage for important elements of Mati's novel punctal plug delivery system for treatment of ocular indications ("PPDS"), including certain features for retaining the punctal plug within the nasolacrimal system of the eye during drug elution.

Mati is actively prosecuting and maintaining 17 patent families related to many elements of the PPDS platform and related product candidates. At present, a total of 40 patents have been granted or allowed, including 4 U.S. patents issued in the first half of 2014, and 95 applications are pending in the U.S. and various other jurisdictions, including Europe, Japan, Canada, Korea, Israel, China, Brazil, Mexico and India. The earliest filed patent family has a projected expiry date in 2024, with other families projected to expire at different times through 2034.

"We recognize the value of securing patent coverage for our PPDS technology. Mati has an extensive international intellectual property portfolio, including patent applications and several granted patents," commented Bob Butchofsky, Mati's President. "We believe the PPDS platform technology can potentially be used to treat several ocular indications, including glaucoma, post-cataract surgery therapies, ocular allergies and dry eye disease, each representing potentially substantial market opportunities for Mati."

Mati continues to develop, support and maintain its intellectual property portfolio with the goal of providing protection from competitors and further expanding the patent coverage for the PPDS platform. While the protection afforded by intellectual property is subject to uncertainties, Mati believes that its patent portfolio provides meaningful protection for the PPDS delivery platform.

Mati also announced today that it has registered the trademark Evolute® as a potential brand name for the PPDS platform.

View original press release